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Summary: L-Aspartic acid-/%7-amido-4-methylcoumarin is a sensitive and 
specific fluorogenic substrate for lysosomal glycoasparaginase (aspartylgluco- 
saminidase). Fibroblasts and leukocytes from 8 patients with aspartylglucos- 
aminuria, showed 1-7 % of the mean normal glycoasparaginase ctivity. Hetero- 
zygotes howed intermediate activities. Glycoasparaginase activity in chorionic 
villi, cultured trophoblasts, cultured amniotic fluid cells and amniotic fluid was 
readily detectable, indicating that prenatal analysis of aspartylglucosaminuria 
should be possible with this assay./?-Aspartyl-4-methylumbelliferone was syn- 
thesized but this potential substrate can not be used to assay glycoasparaginase 
since it hydrolyses pontaneously. 
Aspartylglucosaminuria (AGU; McKusick 208400) is a rare autosomal recessive 
hereditary disorder of glycoprotein catabolism characterized by severe mental 
retardation with facial and skeletal abnormalities (for review see Aula et al 1982; 
Beaudet and Thomas, 1989). The underlying defect is a deficiency of aspartylgluco- 
saminidase (1-aspartamido-/%N-acetylglucosamine aminohydrolase, EC 3.5.1.26; 
Pollitt et al 1968), which results in accumulation of 2-acetamido-1-/?-(L-asparta- 
mido)-l,2-dideoxy-/~-D-glucose (aspartylglucosamine) in tissues and urine (Palo and 
Mattsson, 1970; Maury, 1979; Aula et al 1980). 
Recent studies by Kaartinen et al (1992) showed that aspartylglucosaminidase in 
fact has a broad substrate specificity. It has activity towards L-asparagine-N- 
acetylglucosamine containing lycoasparagines of various sizes with or without the 
di-N-acetylchitobiose moiety, and even towards /~-L-aspartylmethyl ester. Since the 
specificity of aspartylglucosaminidase is apparently determined by the asparagine 
moiety and not by N-acetylglucosamine, these authors proposed the more appropriate 
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name glycoasparaginase for this enzyme, which emphasizes that aspartylglucosamini- 
dase is in fact an asparaginase. 
Since Makino et al (1966) described the glycoasparaginase say with aspartylgluco- 
samine this has been the assay of choice to diagnose AGU patients and has also 
been used for prenatal diagnosis (Aula et al 1982, 1984). This assay is based on the 
colorimetric determination of free N-acetylglucosamine, which is relatively 
insensitive and susceptible to minor changes in the reagents used. In this paper we 
describe a simple, reproducible, fluorimetric assay for glycoasparaginase using L- 
aspartic acid-/%7-amido-4-methylcoumarin (Asp-AMC). After completion of this 
work Mononen et al (1993) recently published a brief description of the sensitivity 
and specificity of an Asp-AMC-based glycoasparaginase say. Here we describe 
details of our assay and show its usefulness for the pre- and postnatal diagnosis of 
aspartylglucosaminuria and detection of heterozygotes. 
MATERIALS AND METHODS 
Total leukocytes were isolated from heparinized blood as described previously (van 
Diggelen et al 1990) and frozen before use. Skin flbroblasts and amniotic fluid cells 
were cultured according to routine procedures in Ham's F10 medium supplemented 
with 10% fetal bovine serum and antibiotics. The cells were harvested with trypsin 
7 days after the last subculture and stored at -70°C until use. Fibroblasts from 
AGU patients were obtained from the European Human Cell Bank (Rotterdam, The 
Netherlands) and blood samples from AGU patients and their heterozygous parents 
were from Finnish patients. 
For the standard glycoasparaginase say homogenates were prepared by sonic- 
ation of cell material in water. Reaction mixtures consisted of 10/~1 homogenate 
(20/~g protein for fibroblasts; 30/~g for leukocytes) or 10/~1 amniotic fluid and, 20/A 
1.5mmol/L L-aspartic acid-/~-7-amido-4-methylcoumarin (Asp-AMC; Sigma St 
Louis, MO, USA) in McIlvain's phosphate-citrate buffer pH 6.5. 
After incubation for 24 h at 37°C the reactions were terminated by the addition of 
200/A McIlvain's phosphate-citrate buffer pH 4.5, and the fluorescence of7-amido- 
4-methylcoumarine (AMC) was measured on a fluorimeter (Fluoroskan, Titertek) 
using the filter setting of methylumbelliferone (excitation 355 nm, emission 460 nm). 
Protein was determined as described previously (van Diggelen et al 1990). 
RESULTS 
Free 7-amido-4-methylcoumarin (AMC) has an excitation maximum at 345 nm and 
emission maximum at 440 nm. The intensity of emission is virtually constant between 
pH 4 and pH 10.7. Asp-AMC appears to be somewhat unstable at pH 10.7, 
which is a commonly used pH for stopping enzyme assays with 4-methylumbelliferyl 
substrates. We have investigated whether the excitation and emission wavelengths 
used for 4-methylumbelliferone (excitation 355 nm, emission 460 nm) gave acceptable 
results for AMC. At 460nm, fluorescence of AMC is only reduced to 2/3, whereas 
blank readings of Asp-AMC are reduced to 1/3. In contrast to 4-methylumbelliferyl 
substrates, AMC conjugates show considerable fluorescence and the reduction of 
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blank readings is advantageous. These results made us decide to use the excitation 
and emission settings of 4-methylumbelliferone for all experiments described below. 
The properties of glycoasparaginase from leukocytes and fibroblasts were investi- 
gated. The pH optimum was between pH 6 and pH 6.5 (Figure 1), which is high for 
a lysosomal enzyme; moreover the activity does not fall appreciably up to pH 8.5. 
The apparent Km was estimated to be 0.15 mmol/L (Figure 2). The glycoasparaginase 
activity increased nearly linearly with time up to 24h of incubation; using this 
incubation time, a linear relationship between the amount of protein and glycoaspara- 
ginase activity was found up to 50/~g protein (data not shown). From these 
experiments, tandard assay conditions were chosen as described in Materials and 
Methods. Addition of Triton X-100 to standard reaction mixtures (0.25% w/v) had 
no effect on the glycoasparaginase activities in control leukocytes and fibroblasts 
(data not shown). 
Assayed under standard conditions, all 8 investigated AGU patients (5 of Finnish 
descent, 2 from the Netherlands and 1 from Turkey), had a profound deficiency of 
glycoasparaginase in fibroblasts, leukocytes and plasma (Table 1). Carriers showed 
about half normal activity. Plasma appears to be a poor enzyme source for carrier 
detection. 
The glycoasparaginase activity in chorionic villi, cultured chorionic villus cells, 
amniotic fluid cells and amniotic fluid was determined under standard conditions. 
The activities in these cells were comparable to those in leukocytes and fibroblasts 
(Table 2). Unfortunately, no material from AGU affected fetuses was available. 
A more convenient fluorogenic substrate for glycoasparaginase would be a 4- 
methylumbelliferone-based substrate since these substrates do not fluoresce. We have 
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Figure 1 pH dependence ofglycoasparaginase activity: normal leukocytes (D) and fibroblasts 
(A); AGU fibroblasts (O). Reaction conditions as in standard assay, except for pH 
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Figure 2 Michaelis Menten plot of glycoasparaginase activity: normal leukocytes (/~) and 
fibroblasts (/k). Reaction conditions as in standard assay, except for Asp-AMC concentration 
Table 1 Glycoasparaginase activity in fibroblasts, leukocytes and plasma from aspartylglucos- 
aminuria patients and carriers 
Range (Mean 4- SD) 
Fibroblasts 
AGU patients (n = 5) 
AGU carriers (n = 2) 
Normal (n = 18) 
Leukocytes 
AGU patients (n = 4) 
AGU carriers (n = 10) 
Normal (n = 32) 
Plasma 
AGU patients (n = 4) 
AGU carriers (n = 10) 
Normal (n = 6) 
Glycoasparaginase (nmol/24 h per nag protein) 
0.8-2.5 
36; 27 
63-176 (113 ± 39) 
1.7-4.7 
12-41 (24 + 9) 
39 92 (65_+ t3) 
Glycoasparaginase (nmol/24 h per ml) 
1.4-3.8 
48-98 (66 ___ 17) 
68-149 (95 4- 26) 
synthesized fl-aspartyl-4-methylumbell iferone as a potential substrate. Unfortunately, 
this compound hydrolyses pontaneously at pH 6.5 at a rate of about 2% per minute 
at room temperature. The Asp-AMC analogue #-aspartyl-7-amido-4-trif luoro- 
methylcoumarin was also synthesized. This compound was a substrate for glycoaspara- 
ginase but the activity was only 20% of the activity with Asp-AMC and had 
no advantages over Asp-AMC (data not shown). 
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Table 2 Glyeoasparaginase activity in normal ehorionie villi, cultured trophoblasts, amnioeytes 
and amniotie fluid 
Glycoasparaginase (nmol/24 h per mg protein) 
Range (Mean ,+ SD) 
Chorionic villi (n = 11) 28-59 
Cultured trophoblasts (n= 11) 50 121 
Amniocytes (n = 12) 38 120 
Amniotic fluid (n = 19) 17-95 
(nmol/24 h per ml; 16 18 weeks gestation) 
(38 ,+ 9) 
(83 _+ 22) 
(68 -+ 21) 
(32 _+ 13) 
DISCUSSION 
We have defined conditions for a ftuorimetric assay of glycoasparaginase that is 
convenient for the diagnostic laboratory involved in enzyme analysis. These results 
extend the independent observation of Mononen et al (1992) who recently showed 
that h-aspartic acid-fl-7-amido-4-methylcoumarin (Asp-AMC) is a specific and sensitive 
substrate. These authors briefly described an assay using a centrifugal analyser. Their 
glycoasparaginase activities in leukocytes and fibroblasts are of the same order of 
magnitude as ours; these authors found a ratio of activity in control eukocytes over 
that of control fibroblasts of 2.7. By contrast, this ratio with our assay was only 0.6. 
Most clinical laboratories involved in the diagnosis of lysosomal storage disorders 
do not have a centrifugal analyser and commonly use 4-methylumbelliferyl substrates. 
We have therefore developed an assay with end-point measurement and showed that 
the excitation and emission wavelengths of 4-methylumbelliferone (355 and 460 nm) 
can be used adequately for the determination of AMC. 
Our Asp-AMC-based assay is more sensitive and has better eproducibility than 
the conventional glycoasparaginase assay based on the color±metric determination 
of free N-acetylglucosamine (Makino et al 1966). The residual glycoasparaginase 
activities in fibroblasts, leukocytes and plasma of the 8 investigated patients were 
1-7% of the mean control activity. Heterozygotes (n = 12) had reduced activities, 
suggesting the feasibility of carrier detection. With our assay the patient range was 
clearly separated from the preliminary heterozygote range. Using the color±metric 
assay, Aula et al (1974) showed a small overlap between their patient and heterozygote 
ranges based on larger numbers. Our results suggest hat our assay may show better 
separation between patient and carrier values. 
In material obtained from control pregnancies the glycoasparaginase activities 
were readily detectable, suggesting the feasibility of prenatal detection of AGU with 
our fluorimetric assay in the first and second trimesters of pregnancy. 
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